Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Nov;98(11):2467-2483.
doi: 10.1007/s00277-019-03820-w. Epub 2019 Oct 30.

Update on management and progress of novel therapeutics for R/R AML: an Iberian expert panel consensus

Pau Montesinos  1   2 , Juan Bergua  3 , Joana Infante  4 , Jordi Esteve  5 , José Eduardo Guimaraes  6 , Jordi Sierra  7 , Miguel Ángel Sanz  8
Affiliations
Review

Update on management and progress of novel therapeutics for R/R AML: an Iberian expert panel consensus

Pau Montesinos et al. Ann Hematol. 2019 Nov.

Erratum in

Abstract

A significant proportion of adult patients with acute myeloid leukemia (AML) fail to achieve complete remission or will relapse later on after achieving it. Prognosis for relapsed or refractory (R/R) AML patients remains discouraging, with the main curative option still relying on hematopoietic stem cell transplant (HSCT) for those who are eligible. Beyond morphological bone marrow and peripheral blood assessment, evaluation of patient performance status and comorbidities, as well as genetic/molecular characterization, is crucial to make an accurate diagnosis and prognosis, which will be useful to select the most appropriate treatment. Emerging strategies are mainly focusing on the development of immune- and molecular-based approaches. Novel targeted therapies are generally well tolerated, potentially allowing them to be administered alone or in combination with classical chemotherapy agents. Enrolment in clinical trials should be considered first option for R/R AML patients, either as a bridge to HSCT or to benefit from novel therapies that eventually may prolong survival and improve quality of life. An Iberian expert panel has reviewed the recent advances in the management of R/R AML with the aim to develop updated evidence and expert opinion-based recommendations.

Keywords: Acute myeloid leukemia; Refractory; Relapsed; Targeted therapies; Treatment.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources